DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Our study addresses the issue of the clinical reliability of three candidate DPYD and one UGT single nucleotide polymorphisms in predicting 5-fluorouracil- and irinotecan-related adverse events. To this purpose, we took advantage of a large cohort of metastatic colorectal cancer patients treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremolini, Chiara, Del Re, Marzia, Antoniotti, Carlotta, Lonardi, Sara, Bergamo, Francesca, Loupakis, Fotios, Borelli, Beatrice, Marmorino, Federica, Citi, Valentina, Cortesi, Enrico, Moretto, Roberto, Ronzoni, Monica, Tomasello, Gianluca, Zaniboni, Alberto, Racca, Patrizia, Buonadonna, Angela, Allegrini, Giacomo, Ricci, Vincenzo, Di Donato, Samantha, Zagonel, Vittorina, Boni, Luca, Falcone, Alfredo, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814264/
https://www.ncbi.nlm.nih.gov/pubmed/29487697
http://dx.doi.org/10.18632/oncotarget.23559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814264/
https://www.ncbi.nlm.nih.gov/pubmed/29487697
http://dx.doi.org/10.18632/oncotarget.23559

Ejemplares similares